Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVG201
- Development stage
- Preclinical
- Lead developer
- ConverGene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CVG201 is a drug development program by ConverGene focused on the discovery and development of oral, small molecule inhibitors of Bromodomain and Extra-Terminal (BET) proteins. The program specifically targets liquid tumors (hematologic malignancies) such as acute myelogenous leukemia (AML) by blocking BET bromodomain proteins, which in turn suppresses the expression of the MYC oncogene, a key driver of cancer cell growth and survival. Currently in the lead optimization stage of preclinical development, CVG201 leads are designed with a unique core structure intended to differentiate them from other BET inhibitors in clinical development.
02
Targets
BET (BET family proteins)
Beyond the preview
Go deeper on CVG201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVG201.